Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.
In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders.
Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers.
The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; SanofiS. A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 26 | 1.25 Increased by +1.98 K% | 1.24 Increased by +0.81% |
| Oct 30, 25 | 2.90 Increased by +680.00% | 1.44 Increased by +101.39% |
| Jul 31, 25 | -0.51 Decreased by -292.31% | -0.70 Increased by +27.14% |
| May 1, 25 | -0.01 Increased by +98.08% | -0.37 Increased by +97.30% |
| Feb 13, 25 | 0.06 Increased by +105.45% | -0.14 Increased by +142.86% |
| Oct 31, 24 | -0.50 Decreased by -143.48% | -0.39 Decreased by -28.21% |
| Aug 1, 24 | -0.13 Increased by +94.12% | -1.08 Increased by +87.96% |
| May 2, 24 | -0.52 Increased by +62.86% | -1.18 Increased by +55.93% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 1.10 B Increased by +84.95% | 186.42 M Increased by +322.56% | Increased by +16.99% Increased by +220.34% |
| Sep 30, 25 | 1.25 B Increased by +149.35% | 251.08 M Increased by +325.05% | Increased by +20.10% Increased by +190.25% |
| Jun 30, 25 | 773.69 M Increased by +17.26% | -66.28 M Decreased by -292.43% | Decreased by -8.57% Decreased by -234.67% |
| Mar 31, 25 | 594.19 M Increased by +20.20% | -57.48 M Increased by +12.82% | Decreased by -9.67% Increased by +27.47% |
| Dec 31, 24 | 593.17 M Increased by +34.90% | -83.76 M Increased by +39.24% | Decreased by -14.12% Increased by +54.96% |
| Sep 30, 24 | 500.92 M Decreased by -33.26% | -111.57 M Decreased by -175.51% | Decreased by -22.27% Decreased by -213.14% |
| Jun 30, 24 | 659.83 M Increased by +107.00% | -16.89 M Increased by +93.88% | Decreased by -2.56% Increased by +97.04% |
| Mar 31, 24 | 494.33 M Increased by +54.82% | -65.94 M Increased by +62.13% | Decreased by -13.34% Increased by +75.54% |